Impact of MHC class I diversity on immune control of immunodeficiency virus replication
- PMID: 18617886
- PMCID: PMC2963026
- DOI: 10.1038/nri2357
Impact of MHC class I diversity on immune control of immunodeficiency virus replication
Abstract
The recent failure of the T-cell-based HIV vaccine trial led by Merck & Co., Inc. prompts the urgent need to refocus on the question of which T-cell responses are required to control HIV replication. The well-described association between the expression of particular MHC class I molecules and successful containment of HIV or, in the macaque model, SIV replication provide a valuable starting point from which to evaluate more precisely what might constitute effective CD8(+) T-cell responses. Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future.
Figures
Similar articles
-
Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.J Gen Virol. 2007 Feb;88(Pt 2):652-659. doi: 10.1099/vir.0.82469-0. J Gen Virol. 2007. PMID: 17251584
-
Relevance of studying T cell responses in SIV-infected rhesus macaques.Trends Microbiol. 2008 Dec;16(12):605-11. doi: 10.1016/j.tim.2008.08.010. Epub 2008 Oct 27. Trends Microbiol. 2008. PMID: 18964016 Free PMC article. Review.
-
Vaccine-induced CD8+ T cells control AIDS virus replication.Nature. 2012 Nov 1;491(7422):129-33. doi: 10.1038/nature11443. Epub 2012 Sep 30. Nature. 2012. PMID: 23023123 Free PMC article.
-
Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.J Virol. 2012 Sep;86(17):9188-200. doi: 10.1128/JVI.00532-12. Epub 2012 Jun 13. J Virol. 2012. PMID: 22696662 Free PMC article.
-
Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.Immunol Rev. 1999 Aug;170:127-34. doi: 10.1111/j.1600-065x.1999.tb01334.x. Immunol Rev. 1999. PMID: 10566147 Review.
Cited by
-
Control of HIV-1 Replication by CD8+ T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection.J Virol. 2022 Oct 12;96(19):e0081122. doi: 10.1128/jvi.00811-22. Epub 2022 Sep 26. J Virol. 2022. PMID: 36154612 Free PMC article.
-
MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population.J Clin Immunol. 2021 Aug;41(6):1154-1161. doi: 10.1007/s10875-021-01071-x. Epub 2021 May 29. J Clin Immunol. 2021. PMID: 34050837 Free PMC article.
-
Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1.PLoS Biol. 2013;11(4):e1001523. doi: 10.1371/journal.pbio.1001523. Epub 2013 Apr 2. PLoS Biol. 2013. PMID: 23565057 Free PMC article.
-
Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion.AIDS Res Hum Retroviruses. 2013 Mar;29(3):602-12. doi: 10.1089/AID.2012.0171. Epub 2013 Jan 8. AIDS Res Hum Retroviruses. 2013. PMID: 23140171 Free PMC article.
-
Temporal association of HLA-B*81:01- and HLA-B*39:10-mediated HIV-1 p24 sequence evolution with disease progression.J Virol. 2012 Nov;86(22):12013-24. doi: 10.1128/JVI.00539-12. Epub 2012 Aug 29. J Virol. 2012. PMID: 22933291 Free PMC article.
References
-
- HIV vaccine failure prompts Merck to halt trial. [News in Brief] Nature. 2007;449:390. - PubMed
-
- Fellay D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944–947. This study confirms and highlights the central role of HLA in immune control of HIV, in particular that of HLA-B*57, but also suggests an unexpectedly important role for HLA-C. - PMC - PubMed
-
- Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523–526. - PubMed
-
- Lyles RH, et al. Natural history of HIV-1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis. 2000;181:872–880. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI052056/AI/NIAID NIH HHS/United States
- R24 RR015371-12/RR/NCRR NIH HHS/United States
- R24 RR016038/RR/NCRR NIH HHS/United States
- R24 RR016038-11/RR/NCRR NIH HHS/United States
- R21 AI077472-02/AI/NIAID NIH HHS/United States
- R01 AI046995/AI/NIAID NIH HHS/United States
- R21 AI077472/AI/NIAID NIH HHS/United States
- R01 AI076114-05/AI/NIAID NIH HHS/United States
- R01 AI052056-05/AI/NIAID NIH HHS/United States
- R01 AI46995/AI/NIAID NIH HHS/United States
- R24 RR015371/RR/NCRR NIH HHS/United States
- R01 AI076117/AI/NIAID NIH HHS/United States
- R01 AI076114/AI/NIAID NIH HHS/United States
- R01 AI049120/AI/NIAID NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- R01 AI049120-09/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials